Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with alpelisib for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
- Associated Therapies
- -
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.
- Conditions
- Interventions
- First Posted Date
- 2015-05-07
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 572
- Registration Number
- NCT02437318
- Locations
- 🇺🇸
Lahey Clinic, Burlington, Massachusetts, United States
🇺🇸Virginia Cancer Specialists SC, Fairfax, Virginia, United States
🇺🇸Highlands Oncology Group, Fayetteville, Arkansas, United States
Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2015-04-21
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 726
- Registration Number
- NCT02422615
- Locations
- 🇺🇸
UCLA Medical Center ., Los Angeles, California, United States
🇺🇸Florida Cancer Research Institute Dept of Oncology, Davie, Florida, United States
🇺🇸UF Health Cancer Center at Orlando Health, Orlando, Florida, United States
Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2016-06-15
- Lead Sponsor
- Consorzio Oncotech
- Target Recruit Count
- 745
- Registration Number
- NCT02404051
- Locations
- 🇮🇹
Azienda Ospedaliera Policlinico di Bari, Bari, Italy
🇮🇹A.O.R.N.A.S. Garibaldi Nesima di Catania, Catania, Italy
🇮🇹Presidio Ospedaliero Antonio Perrino, Brindisi, Italy
Overcoming Endocrine Resistance in Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2016-06-15
- Lead Sponsor
- Consorzio Oncotech
- Target Recruit Count
- 396
- Registration Number
- NCT02394496
- Locations
- 🇮🇹
Ospedale Sacro Cuore - Don Calabria U.O.C. Oncologia Medica, Negrar, Verona, Italy
🇮🇹Azienda Ospedaliera Treviglio-Caravaggio U.O. Oncologia Medica, Treviglio, Bergamo, Italy
🇮🇹Presidio Ospedaliero di Vallo della Lucania U.O. Oncologia Medica, Vallo Della Lucania, Salerno, Italy
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 33
- Registration Number
- NCT02392611
A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-03-10
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 70
- Registration Number
- NCT02384239
- Locations
- 🇺🇸
Georgetown University, Washington, District of Columbia, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
Phase I Study of the Combination of MLN9708 and Fulvestrant
- First Posted Date
- 2015-03-10
- Last Posted Date
- 2019-04-29
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 9
- Registration Number
- NCT02384746
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC Patients
- First Posted Date
- 2015-03-09
- Last Posted Date
- 2016-06-15
- Lead Sponsor
- Consorzio Oncotech
- Target Recruit Count
- 156
- Registration Number
- NCT02383030
- Locations
- 🇮🇹
Ospedale 'Felice Lotti' - Azienda USL 5 di Pisa U.O. di Oncologia Medica, Pontedera, Pisa, Italy
🇮🇹Ospedale Oncologico Regionale - Centro di Riferimento Oncologico di Basilicata U.O. di Oncologia Medica, Rionero in vulture, Potenza, Italy
🇮🇹Ospedale Unico Versilia U.O. Oncologia Medica, Lido Di Camaiore, Lucca, Italy
Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant
- First Posted Date
- 2015-02-27
- Last Posted Date
- 2018-12-14
- Lead Sponsor
- Celgene
- Target Recruit Count
- 97
- Registration Number
- NCT02374099
- Locations
- 🇺🇸
Florida Cancer Specialists, West Palm Beach, Florida, United States
🇧🇪Clinique Sainte Elisabeth - Service d'Oncologie, Namur, Belgium
🇩🇪Universitatsklinikum Hamburg-Eppendorf / IVDP, Hamburg, Germany
Detect V / CHEVENDO (Chemo vs. Endo)
- Conditions
- Interventions
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Prof. Wolfgang Janni
- Target Recruit Count
- 271
- Registration Number
- NCT02344472
- Locations
- 🇩🇪
University Hospital Ulm Gynecology/Obstetrics, Ulm, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.